Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.22
AVEO's Cash-to-Debt is ranked lower than
66% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. AVEO: 2.22 )
Ranked among companies with meaningful Cash-to-Debt only.
AVEO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.54  Med: 5.37 Max: N/A
Current: 2.22
Equity-to-Asset 0.10
AVEO's Equity-to-Asset is ranked lower than
89% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. AVEO: 0.10 )
Ranked among companies with meaningful Equity-to-Asset only.
AVEO' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.21  Med: 0.46 Max: 0.79
Current: 0.1
-3.21
0.79
Piotroski F-Score: 2
Altman Z-Score: -20.79
Beneish M-Score: -0.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -435.88
AVEO's Operating Margin % is ranked lower than
72% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. AVEO: -435.88 )
Ranked among companies with meaningful Operating Margin % only.
AVEO' s Operating Margin % Range Over the Past 10 Years
Min: -8035.89  Med: -198.82 Max: 20.59
Current: -435.88
-8035.89
20.59
Net Margin % -465.60
AVEO's Net Margin % is ranked lower than
73% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. AVEO: -465.60 )
Ranked among companies with meaningful Net Margin % only.
AVEO' s Net Margin % Range Over the Past 10 Years
Min: -8277.57  Med: -212.81 Max: 18.59
Current: -465.6
-8277.57
18.59
ROE % -221.74
AVEO's ROE % is ranked lower than
92% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. AVEO: -221.74 )
Ranked among companies with meaningful ROE % only.
AVEO' s ROE % Range Over the Past 10 Years
Min: -116.49  Med: -79.3 Max: 20.76
Current: -221.74
-116.49
20.76
ROA % -72.14
AVEO's ROA % is ranked lower than
79% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. AVEO: -72.14 )
Ranked among companies with meaningful ROA % only.
AVEO' s ROA % Range Over the Past 10 Years
Min: -88.25  Med: -48.61 Max: 13.74
Current: -72.14
-88.25
13.74
ROC (Joel Greenblatt) % -26404.81
AVEO's ROC (Joel Greenblatt) % is ranked lower than
94% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. AVEO: -26404.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVEO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1269.33  Med: -769.44 Max: 689.47
Current: -26404.81
-1269.33
689.47
3-Year Revenue Growth Rate -8.40
AVEO's 3-Year Revenue Growth Rate is ranked lower than
65% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AVEO: -8.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVEO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -71.55 Max: -8.4
Current: -8.4
3-Year EBITDA Growth Rate -71.80
AVEO's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. AVEO: -71.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AVEO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -71.8 Max: -2.4
Current: -71.8
3-Year EPS without NRI Growth Rate -53.20
AVEO's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. AVEO: -53.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVEO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -54.2 Max: -3
Current: -53.2
GuruFocus has detected 3 Warning Signs with AVEO Pharmaceuticals Inc $AVEO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AVEO Guru Trades in Q1 2016

Jim Simons 2,094,900 sh (+6.02%)
Paul Tudor Jones 83,869 sh (unchged)
» More
Q2 2016

AVEO Guru Trades in Q2 2016

Jim Simons 2,405,400 sh (+14.82%)
Paul Tudor Jones 83,869 sh (unchged)
» More
Q3 2016

AVEO Guru Trades in Q3 2016

Jim Simons 2,595,400 sh (+7.90%)
Paul Tudor Jones 83,869 sh (unchged)
» More
Q4 2016

AVEO Guru Trades in Q4 2016

Jim Simons 2,743,900 sh (+5.72%)
Paul Tudor Jones 83,869 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:NBY, OTCPK:COTQF, OTCPK:AMEUF, AMEX:RNN, OTCPK:NWBO, AMEX:PIP, OTCPK:IGXT, OTCPK:TBQBF, NAS:NTEC, NAS:BLRX, OTCPK:CELZ, NAS:CAPR, NAS:BUR, OTCPK:THCBF, NAS:ARGS, NAS:PBMD, NAS:DMPI, OTCPK:LVCLF, NAS:TRIL, AMEX:AMPE » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc is a biopharmaceutical company. It is involved in discovering, developing and commercializing novel cancer therapeutics.

AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.

Ratios

vs
industry
vs
history
PB Ratio 16.81
AVEO's PB Ratio is ranked lower than
91% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AVEO: 16.81 )
Ranked among companies with meaningful PB Ratio only.
AVEO' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.06 Max: 22.25
Current: 16.81
0.87
22.25
PS Ratio 7.75
AVEO's PS Ratio is ranked higher than
54% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. AVEO: 7.75 )
Ranked among companies with meaningful PS Ratio only.
AVEO' s PS Ratio Range Over the Past 10 Years
Min: 0.63  Med: 4.55 Max: 101.25
Current: 7.75
0.63
101.25
Current Ratio 5.00
AVEO's Current Ratio is ranked higher than
64% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. AVEO: 5.00 )
Ranked among companies with meaningful Current Ratio only.
AVEO' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.78 Max: 9.47
Current: 5
1.47
9.47
Quick Ratio 5.00
AVEO's Quick Ratio is ranked higher than
65% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. AVEO: 5.00 )
Ranked among companies with meaningful Quick Ratio only.
AVEO' s Quick Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.78 Max: 9.47
Current: 5
1.47
9.47
Days Sales Outstanding 60.37
AVEO's Days Sales Outstanding is ranked higher than
52% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. AVEO: 60.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.19  Med: 38.64 Max: 390.8
Current: 60.37
3.19
390.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.90
AVEO's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. AVEO: -9.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVEO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.9  Med: -8.2 Max: 0
Current: -9.9
-13.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 26.34
AVEO's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. AVEO: 26.34 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVEO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.42  Med: 3.6 Max: 29.67
Current: 26.34
1.42
29.67
Price-to-Tangible-Book 16.81
AVEO's Price-to-Tangible-Book is ranked lower than
86% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. AVEO: 16.81 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVEO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 3.2 Max: 18.94
Current: 16.81
1.2
18.94
Price-to-Median-PS-Value 1.71
AVEO's Price-to-Median-PS-Value is ranked lower than
80% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. AVEO: 1.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVEO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.05 Max: 20.41
Current: 1.71
0.16
20.41
Earnings Yield (Greenblatt) % -61.30
AVEO's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. AVEO: -61.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVEO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.7  Med: 164.4 Max: 48140
Current: -61.3
6.7
48140

More Statistics

Revenue (TTM) (Mil) $5.99
EPS (TTM) $ -0.45
Beta1.61
Short Percentage of Float1.96%
52-Week Range $0.54 - 1.23
Shares Outstanding (Mil)75.86
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
Aveo Cancer Drug Tivozanib Clears Safety Review Feb 24 2017
AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review Feb 23 2017
AVEO Announces Clinical and Regulatory Updates for Tivozanib Feb 09 2017
AVEO to Present at the 19th Annual BIO CEO & Investor Conference Feb 06 2017
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Jan 12 2017
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement Jan 05 2017
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Jan 04 2017
ETFs with exposure to AVEO Pharmaceuticals, Inc. : December 22, 2016 Dec 22 2016
How AVEO Pharmaceuticals, Inc. (AVEO) Stacks Up Against Its Peers? Dec 13 2016
ETFs with exposure to AVEO Pharmaceuticals, Inc. : December 12, 2016 Dec 12 2016
AVEO Partner Submits Response to Questions on Tivozanib Nov 29 2016
AVEO Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing... Nov 28 2016
AVEO to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 22 2016
AVEO PHARMACEUTICALS INC Financials Nov 11 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : November 10, 2016 Nov 10 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 08 2016
AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016 Nov 08 2016
AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected Nov 07 2016
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q3 Nov 04 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)